cells

Prostate Cancer Clinical Trials
Enrolling Now

Castration-Resistant Prostate Cancer (ARC-6)

Overview

A Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant-based combination therapy in participants with metastatic castrate resistant prostate cancer.

Key Eligibility Criteria

  • Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nmol/L or 50 ng/dL)
  • Naive to any prior treatment with immune checkpoint blockade therapy

ARC-6 Clinical Trial Locations

clinicaltrials.gov

arrow

Castration-Resistant Prostate Cancer (ARC-5)

Overview

A Phase 1/1b open-label dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant in combination with zimberelimab in participants with advanced malignancies, including castration-resistant prostate cancer and renal cell carcinoma.

Key Eligibility Criteria

  • Clear-cell renal cell carcinoma:
    • May have received up to 2 prior lines of therapy, one of which must have included an anti-PD-(L)1 based therapy
    • Participants who progressed within 16 weeks during an anti-PD-(L)1 therapy are excluded
  • Metastatic castration-resistant prostate cancer:
    • Prior therapy must include 1 line of a taxane-containing regimen (or documentation that the physician and participant consider a taxane regimen inappropriate) and an androgen synthesis inhibitor
    • Prior treatment with immunotherapy (including but not limited to anti-PD-(L)1 or anti-CTLA-4 antagonists, sipuleucel-T, etc) is not permitted

ARC-5 Clinical Trial Locations

clinicaltrials.gov

arrow